PeptideJournal
Guides15 min read

Best Peptides for Skin Wound Healing

Your skin is your largest organ, and when it is damaged — by a cut, a burn, surgery, or a chronic condition like diabetes — the repair process involves a tightly coordinated sequence of events. Inflammation clears debris. New blood vessels form. Fibroblasts lay down collagen.

Your skin is your largest organ, and when it is damaged — by a cut, a burn, surgery, or a chronic condition like diabetes — the repair process involves a tightly coordinated sequence of events. Inflammation clears debris. New blood vessels form. Fibroblasts lay down collagen. Keratinocytes migrate across the wound surface. Eventually, the tissue remodels into something approximating the original structure, though rarely matching it perfectly.

Scars are the visible evidence that this process is imperfect. Collagen gets deposited in disorganized bundles. The new tissue lacks the elasticity, texture, and strength of uninjured skin. In some cases — keloids, hypertrophic scars, chronic diabetic ulcers — the healing process goes seriously wrong.

Peptides offer a way to intervene at the molecular level. They can stimulate collagen production, control inflammation, accelerate keratinocyte migration, promote blood vessel growth, and reduce scar formation. Some are already in clinical trials. Others sit quietly in your skincare products, doing more work than most people realize.

Here is what the research says about the best peptides for skin wound healing and scar reduction.

Table of Contents

The Wound Healing Process: A Quick Primer

Skin wound healing happens in four overlapping phases:

1. Hemostasis (minutes): Platelets aggregate and release growth factors that recruit immune cells.

2. Inflammation (days 1-6): Neutrophils and macrophages clear bacteria and debris. Controlled inflammation is necessary, but excessive inflammation leads to chronic wounds and worse scarring.

3. Proliferation (days 4-21): Fibroblasts produce collagen. New blood vessels form (angiogenesis). Keratinocytes migrate across the wound to restore the epithelial barrier.

4. Remodeling (weeks to months): Type III collagen is replaced by stronger type I collagen. This phase can last up to two years and determines the final scar appearance.

The most effective wound-healing peptides act across multiple phases rather than targeting just one.

Peptide Comparison Table

PeptidePrimary ActionsCollagen EffectAnti-Scar EvidenceHuman Clinical DataDelivery
GHK-CuCollagen synthesis, ECM remodeling, gene regulationIncreases types I, IV, VII; up to 70% boost in vitroModerateYes (multiple clinical trials)Topical, injectable
TB-500 / TB-500Cell migration, angiogenesis, anti-inflammatoryIncreases deposition, reduces scar collagen densityStrong (animal)Phase II trialsInjectable, topical
BPC-157Angiogenesis, granulation tissue, VEGF activationIncreases collagen deposition and organizationModerate (animal)Very limitedInjectable, topical
MatrixylSignal peptide: collagen and fibronectin synthesisIncreases types I, III, IV; fibronectin, elastinModerate (animal)Yes (clinical studies)Topical
LL-37Antimicrobial, re-epithelialization, antifibroticSuppresses excess collagen (antifibrotic)ModeratePhase I trialTopical (formulated)
KPVAnti-inflammatory (NF-kB inhibition), antimicrobialModulates collagen metabolismModerate (animal)LimitedTopical, injectable, oral
Palmitoyl-GDPHCell migration, re-epithelializationIncreases depositionModerate (animal)NoneTopical
alphaCT1Cx43 modulation, gap junction regulationRemodels collagen organizationStrongPhase II trial (47% scar improvement)Topical

1. GHK-Cu (Copper Tripeptide)

GHK-Cu is a naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine. It was first isolated in the 1970s and has four decades of research behind it — more than almost any other regenerative peptide in skincare.

What the Research Shows

GHK-Cu stimulates collagen synthesis at concentrations as low as 0.01 nanomolar. In laboratory studies, it increased production of collagen types I, IV, and VII, plus elastin, fibronectin, and glycosaminoglycans [1]. Combined with LED irradiation (625-635 nanometers), GHK boosted collagen synthesis by 70% and basic fibroblast growth factor (bFGF) production by 230% compared to LED alone [1].

In wound models, GHK-Cu accelerated healing in healthy rats, diabetic rats, and ischemic wound models. A collagen dressing incorporating GHK increased collagen content ninefold in healthy rat wounds, with better epithelialization and increased fibroblast activation [2]. In ischemic open wounds — relevant to chronic wounds in people with poor circulation — GHK-Cu sped up healing and decreased metalloproteinases 2 and 9 plus TNF-beta versus vehicle alone [2].

Clinical results back up the preclinical data. In a randomized, double-blind trial, GHK-Cu outperformed Matrixyl 3000, producing a 31.6% reduction in wrinkle volume over 8 weeks [3]. A pilot study found topical copper tripeptide complexes increased skin thickness, improved hydration, and stimulated collagen I production [3].

Gene expression analysis reveals that GHK-Cu regulates over 1,500 human genes. It modulates metalloproteinases and their inhibitors (TIMP1, TIMP2), controls ECM breakdown and rebuilding, and suppresses inflammatory molecules including NF-kB [1]. This is not a peptide that does one thing.

How It Works

The copper ion is an essential cofactor for lysyl oxidase and lysyl hydroxylase — enzymes that cross-link collagen fibers and give them stability. GHK-Cu increases both MMP2 (which breaks down old, disorganized collagen) and TIMPs (which protect new collagen). This balance between breakdown and rebuilding drives productive scar remodeling rather than just more collagen accumulation.

Limitations

Injectable forms of GHK-Cu are currently prohibited for commercial compounding by FDA regulations as of 2023. Topical formulations are widely available but vary in quality and concentration. Larger clinical trials are needed. For more depth, see our complete GHK-Cu guide and copper peptides skincare overview.

2. Thymosin Beta-4 / TB-500

Thymosin beta-4 (TB4) is a 43-amino-acid peptide found in nearly every human tissue. TB-500 is a synthetic version built around the active fragment LKKTETQ (amino acids 17-23), responsible for its actin-binding, cell migration, and wound healing activity.

What the Research Shows

In the foundational study by Malinda et al. (1999), topical or intraperitoneal TB4 increased re-epithelialization of full-thickness rat wounds by 42% at 4 days and up to 61% at 7 days versus saline controls. Treated wounds showed increased collagen deposition and angiogenesis [4]. TB4 also stimulated keratinocyte migration 2- to 3-fold in just 4 to 5 hours at doses as low as 10 picograms [4].

Across multiple models — normal rats, steroid-treated rats, diabetic mice, aged mice — TB4 consistently accelerated dermal healing, including for burns [5]. Two Phase II clinical trials in stasis and pressure ulcers showed TB4 accelerated wound closure by almost a month compared to placebo. It was safe and well tolerated [5].

A 2024 study added an interesting twist: TB-500's wound-healing activity may actually come from its metabolite Ac-LKKTE rather than the parent compound [6].

How It Works

TB4 sequesters G-actin, maintaining the monomeric actin pool cells need for rapid filament assembly during migration. It also promotes stem cell mobilization, inhibits inflammation and apoptosis, and has antimicrobial properties. Different fragments carry different activities: amino acids 1-4 are anti-inflammatory, 1-15 are cytoprotective, and 17-23 handle cell migration, wound healing, and angiogenesis [5]. Reduced myofibroblast numbers in treated wounds likely explain the observed reduction in scarring.

Limitations

TB-500 is classified as a Category 2 bulk drug substance per 2023 FDA guidance and is not approved for human therapeutic use. WADA prohibits it in competitive sports. The theoretical risk of enhanced angiogenesis in people with malignancies needs consideration. For full details, see our TB-500 research profile.

3. BPC-157

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from gastric juice protein. While best known for musculoskeletal healing, its wound repair properties are well documented.

What the Research Shows

Seiwerth et al. established that BPC-157 promotes collagen formation, inflammatory cell response, and angiogenesis as a coordinated triad — appearing earlier and progressing faster in treated animals than controls [7].

In alkali-burn wound models, BPC-157 significantly improved healing in rats. At 18 days, treated wounds showed better granulation tissue, re-epithelialization, and higher collagen deposition — comparable to basic fibroblast growth factor (bFGF) [8].

BPC-157's wound healing activity operates in a very low dose range. The entire repair cascade — inflammation control, collagen deposition, angiogenesis, granulation tissue development, and epithelium restoration — was significantly improved versus controls [7].

At the molecular level, BPC-157 upregulates VEGF-a and accelerates vascular tube formation through both VEGF-dependent and VEGF-independent pathways. Gene expression analysis shows it increases expression of 19 angiogenic signaling genes within 10 minutes of application [8].

How It Works

BPC-157 promotes wound healing through several parallel pathways: VEGF-driven angiogenesis, fibroblast activation, collagen and ECM deposition, and upregulation of cytoprotective factors like heme oxygenase-1 (HO-1) and heat shock proteins. It also reduces oxidative stress and preserves mitochondrial integrity in wounded tissue.

Limitations

Human wound healing data for BPC-157 is essentially nonexistent. The three existing human studies focused on knee pain, interstitial cystitis, and pharmacokinetics — not skin wounds. See our best peptides for wound healing guide for broader context.

4. Matrixyl (Palmitoyl Pentapeptide-4)

Matrixyl is a synthetic signal peptide containing five amino acids (KTTKS) attached to a palmitic acid chain that helps it penetrate the skin's lipid barrier. It is classified as a matrikine — a messenger peptide that regulates cell behavior through specific receptors.

What the Research Shows

The pentapeptide sequence KTTKS was identified as the minimum fragment needed to potently stimulate collagen and fibronectin production in mesenchymal cells [9]. Matrixyl boosts collagen types I, III, and IV, plus elastin, fibronectin, and glucosaminoglycans. It also accelerates procollagen production and regulates hyaluronic acid synthesis in fibroblasts [9].

A wound healing study published in ACS Omega compared Matrixyl delivered via patch versus cream in rats. Wound healing improved from 63.5% to 81.81% in treatment groups versus controls. Patch delivery achieved 89% collagen formation, compared to 65.3% for cream — showing that delivery method significantly impacts results [10]. A separate 2016 study suggested palmitoyl-KTTKS could serve as a therapeutic agent for scar prevention based on its balance of wound healing and collagen-modulating properties [10].

For anti-aging, a 12-week double-blind study in 93 women showed significant wrinkle reduction versus placebo [9].

How It Works

After penetrating the stratum corneum, Matrixyl binds to cell-surface receptors in the dermis and triggers collagen biosynthesis through the TGF-beta signaling pathway. Its effect on collagen types I and III relates primarily to increased biosynthesis rather than changes in export or degradation pathways.

Limitations

Matrixyl is primarily formulated for anti-aging skincare rather than acute wound treatment. Its wound healing data, while promising, is limited to animal studies. It is widely available in over-the-counter products, but concentration and formulation quality vary considerably. For related peptides, see our Matrixyl 3000 and Matrixyl Synthe'6 profiles, plus our broader best peptides for skin anti-aging guide.

5. LL-37 (Human Cathelicidin)

LL-37 is a 37-amino-acid antimicrobial peptide produced naturally by your skin after injury. It is part of the cathelicidin family — your first line of immune defense in epithelial tissues.

What the Research Shows

LL-37 plays a dual role in wound healing: it fights infection and actively promotes tissue repair. Topical application of synthetic LL-37 increased vascularization and re-epithelialization in wound models, demonstrating a direct role in wound regeneration through blood vessel formation [11].

What makes LL-37 unique is its antifibrotic property. In human dermal keloids, fibrosis was inversely related to cathelicidin expression. At nanomolar concentrations, LL-37 inhibited baseline and TGF-beta-induced collagen expression by activating the ERK signaling pathway [12]. Put simply, LL-37 suppresses the excess collagen production that causes keloids and hypertrophic scars.

LL-37 also has broad-spectrum antimicrobial activity — it disrupts bacterial membranes, recruits immune cells, and modulates both innate and adaptive immune responses [11]. This matters because wound infection is one of the biggest obstacles to healing. Notably, LL-37 is absent from the epithelium of chronic ulcers, which may partly explain why these wounds fail to close. Nanoparticle lipid carriers delivering LL-37 have been shown to speed wound closure and reduce inflammation in laboratory and animal models [11].

The peptide is currently in Phase I clinical trials for leg ulcers.

How It Works

LL-37 kills bacteria directly, recruits immune cells, stimulates keratinocyte migration, promotes angiogenesis through VEGF-A upregulation, and suppresses fibrotic collagen through ERK signaling. This combination of antimicrobial, pro-healing, and anti-scarring effects is unusual — most peptides do not cover all three.

Limitations

LL-37 is challenging to formulate for topical delivery due to stability issues. It is not yet commercially available as a wound treatment. The clinical trial pipeline is early-stage. For more background, see our LL-37 research overview.

6. KPV (Alpha-MSH Fragment)

KPV is a tripeptide (Lysine-Proline-Valine) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains the anti-inflammatory activity of the parent hormone without its pigment-inducing effects.

What the Research Shows

KPV reduces inflammation by blocking the NF-kB pathway and lowering TNF-alpha and IL-6 production. In skin wound models, it accelerated wound closure and reduced scar formation while minimizing inflammatory markers [13].

A study in juvenile mice showed that surgical incisions treated with KPV healed better by days 3 and 7, with fewer leukocytes and mast cells. By days 40 and 60, KPV-treated mice had smaller scar areas than controls [13]. The scar-reducing benefit appears tied to collagen metabolism modulation — KPV reduces the inflammation that leads to hypertrophic scarring, resulting in smaller scars [13].

KPV also has antimicrobial effects, significantly inhibiting Staphylococcus aureus colony formation — relevant because S. aureus is a major cause of wound infections [13]. For inflammatory skin conditions tied to wound healing (eczema, psoriasis, dermatitis), animal models show topical KPV mitigated symptoms and sped up skin barrier restoration [13].

How It Works

KPV suppresses NF-kB activation through both melanocortin receptor-dependent and receptor-independent pathways. It promotes tight junction integrity and inhibits IL-1-beta production. Unlike alpha-MSH, KPV does not stimulate melanin production — useful for wound healing without pigmentation side effects.

Limitations

Most KPV wound healing data comes from animal models. Human clinical trials for skin wound healing have not been published. The peptide is available through research suppliers but is not approved for therapeutic use. For related reading, see our guide on best peptides for inflammation.

7. Palmitoyl-GDPH

Palmitoyl-GDPH is a fatty acid-conjugated tetrapeptide that emerged from drug discovery efforts targeting skin wound repair. In vivo, topical treatment on rats for 18 days increased re-epithelialization, boosted collagen deposition, and diminished scar formation compared to untreated controls — with no significant systemic toxicity [14]. The palmitic acid conjugation increases lipophilicity, helping the peptide penetrate through the skin's sebum layer to reach dermal fibroblasts.

Research is limited to a small number of preclinical studies. No human data exists, and the peptide is not widely available commercially.

8. Alpha Connexin Carboxy-Terminus 1 (alphaCT1)

AlphaCT1 is a peptide mimic of the carboxyl terminus of connexin 43 (Cx43), a gap junction protein. It has the most advanced clinical scar reduction data of any peptide in this guide.

What the Research Shows

In Phase II clinical trials, acute treatment of surgical skin wounds with alphaCT1 improved scar appearance by 47% at nine months post-surgery [15]. This is a remarkable result for a topical peptide applied at the time of wound closure.

In preclinical models (mice and pigs), alphaCT1 increased wound closure rate and reduced inflammatory neutrophil infiltration. Histological analysis of treated human wounds showed a collagen scar matrix that more closely resembled unwounded skin — organized architecture rather than the disorganized bundles typical of scars [15].

How It Works

AlphaCT1 modulates gap junction communication between cells in the wound environment. Cx43 is upregulated around wound edges and influences the inflammatory response and fibroblast behavior. AlphaCT1 appears to temper inflammation and redirect collagen organization toward normal skin patterns rather than scar tissue [15].

Limitations

AlphaCT1 is not commercially available as a consumer product. It remains in the clinical trial pipeline. Its mechanism involving gap junction modulation is less intuitive and less well understood than collagen-stimulating peptides.

Topical vs. Injectable Peptides for Wound Healing

How you deliver a peptide matters as much as which peptide you choose.

Topical application works best for surface wounds, post-surgical healing, and chronic ulcers. GHK-Cu creams, Matrixyl serums, and LL-37 nanoformulations fall here. The challenge is penetration — the stratum corneum blocks most molecules. Lipophilic conjugation (palmitoyl groups), liposomes, and microneedle patches all improve delivery [10].

Injectable delivery (subcutaneous or local injection) puts the peptide directly into target tissue. BPC-157, TB-500, and KPV are typically administered this way in research settings. This approach bypasses the skin barrier but requires medical supervision.

For topical peptides, formulation quality matters enormously. A peptide dissolved in an inappropriate vehicle will sit on the skin surface and do nothing.

Frequently Asked Questions

Which peptide is best for reducing scars?

AlphaCT1 has the strongest clinical evidence — a 47% improvement in scar appearance at 9 months in a Phase II trial [15]. For a more accessible option, GHK-Cu is available topically and has demonstrated collagen remodeling activity that improves scar quality. KPV has shown scar reduction in animal models by controlling wound inflammation.

Can I use peptide skincare products on fresh wounds?

Cosmetic peptide products (Matrixyl serums, copper peptide creams) are formulated for intact skin, not open wounds. Open wounds need sterile, medical-grade formulations. Do not apply cosmetic products to fresh surgical incisions, burns, or open wounds. Talk to your dermatologist or surgeon about appropriate wound-care peptide products.

How does GHK-Cu compare to Matrixyl for wound healing?

Both stimulate collagen synthesis differently. GHK-Cu regulates over 1,500 genes, controls ECM remodeling through balanced MMP/TIMP activity, and delivers copper for collagen cross-linking. Matrixyl is a more targeted signal peptide working through the TGF-beta pathway. GHK-Cu has more wound healing data; Matrixyl has more anti-aging clinical data. See our guides on GHK-Cu and Matrixyl.

Are these peptides effective for diabetic wounds?

GHK-Cu improved diabetic wound healing in rats, and TB4 accelerated repair in diabetic mice [2][5]. Promising but preclinical. No peptide is approved for diabetic wound treatment. If you have diabetic wounds, work with your wound care specialist first.

Can peptides prevent surgical scars?

AlphaCT1 is the closest to clinical proof, with 47% scar improvement when applied at surgery. Matrixyl and GHK-Cu have shown related potential in preclinical models, but neither has been tested in controlled surgical scar trials.

Do oral collagen peptides help with wound healing?

Oral collagen peptides (hydrolyzed collagen supplements) are a different category from the bioactive peptides covered here. They provide amino acid building blocks rather than signaling to repair pathways. Some evidence supports oral collagen for skin hydration and elasticity, but for active wound healing, topically or locally delivered bioactive peptides are more targeted.

The Bottom Line

Peptides for skin wound healing range from research compounds with dramatic preclinical results (BPC-157, TB-500) to clinically proven topical actives you can buy today (GHK-Cu, Matrixyl). The most exciting development may be alphaCT1, which produced a 47% scar improvement in Phase II human trials — a result that could change how surgeons approach wound closure.

For everyday use, GHK-Cu has the deepest evidence base among topical peptides, with decades of research showing collagen stimulation, wound acceleration, and ECM remodeling. Matrixyl is the most widely available option in consumer skincare, with solid collagen-boosting data. For inflammatory skin conditions that impair healing, KPV and LL-37 target the inflammation-wound healing connection from different angles.

The gap between animal models and patient access remains large. But peptide-based wound care is moving toward clinical reality. If you are dealing with slow recovery, problematic scarring, or a chronic wound, ask your dermatologist about the peptide options that match your situation.

For related guides, see best peptides for wound healing and tissue repair, best peptides for skin anti-aging, and best peptides for inflammation reduction.

References

  1. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015. PMC

  2. Pickart L, Vasquez-Soltero JM, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. PMC

  3. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. Journal of Aging Science. PDF

  4. Malinda KM, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364-368. PubMed

  5. Goldstein AL, et al. The regenerative peptide thymosin beta4 accelerates the rate of dermal healing in preclinical animal models and in patients. Annals of the New York Academy of Sciences. 2012;1270:37-44. PubMed

  6. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of Chromatography B. 2024. ScienceDirect

  7. Seiwerth S, et al. BPC 157's effect on healing. Journal of Physiology. 1997;91(3-6):175-178. PubMed

  8. Huang T, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Design, Development and Therapy. 2015;9:2485-2499. PMC

  9. Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics. 2017;4(2):16. MDPI

  10. Matrixyl Patch vs Matrixyl Cream: A Comparative In Vivo Investigation of Matrixyl (MTI) Effect on Wound Healing. ACS Omega. 2022. PMC

  11. Antimicrobial Peptides for Skin Wound Healing. Biomolecules. 2025;15(11):1613. MDPI

  12. Heilborn JD, et al. Collagen synthesis is suppressed in dermal fibroblasts by the human antimicrobial peptide LL-37. Journal of Investigative Dermatology. 2009;129(3):682-689. PMC

  13. Bohm M, et al. Are melanocortin peptides future therapeutics for cutaneous wound healing? Experimental Dermatology. 2019;28(3):219-224. PubMed

  14. Fadilah NIM, et al. Discovery of bioactive peptides as therapeutic agents for skin wound repair. Journal of Tissue Engineering. 2024. PMC

  15. Ghatnekar GS, et al. The Connexin 43 Carboxyl Terminal Mimetic Peptide alphaCT1 Prompts Differentiation of a Collagen Scar Matrix in Humans Resembling Unwounded Skin. International Journal of Molecular Sciences. 2021. PMC